Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma
2020-01-01 Oza, Am; Lorusso, D; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; Weberpals, Ji; Clamp, Ar; Scambia, G; Leary, A; Holloway, Rw; Gancedo Margarita, A; Fong, Pc; Goh, Jc; O'Malley, Dm; Armstrong, Dk; Banerjee, S; García-Donas, J; Swisher, Em; Cella, D; Meunier, J; Goble, S; Cameron, T; Maloney, L; Mörk, A; Bedel, J; Ledermann, Ja; Coleman, Rl
Multicentre Italian Trials in Ovarian cancer (MITO) translational group. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
2016-01-01 Bagnoli, M; Canevari, S; Califano, D; Losito, S; Maio, Md; Raspagliesi, F; Carcangiu ML, ; Toffoli, G; Cecchin, E; Sorio, R; Canzonieri, V; Russo, D; Scognamiglio, G; Chiappetta, G; Baldassarre, G; Lorusso, D; Scambia, G; Zannoni, Gf; Savarese, A; Carosi M, ; Scollo, P; Breda, E; Murgia, V; Perrone, F; Pignata, S; De Cecco, L; Mezzanzanica, D
WEEKLY BOLUS TOPOTECAN IN ADVANCED OR RECURRENT GYNAECOLOGICAL CANCERS
2009-01-01 Lorusso, D; Mainenti, S.; Pietragalla, A.; De Vincenzo, R. P.; Testa, A.; Di Stefano, M. G.; Masciullo, V; Scambia, G.
Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage IIIC-IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study
2018-01-01 Raspagliesi, F; Bogani, G; Matteucci, L; Casarin, J; Sabatucci, I; Tamberi, S; Arcangeli, V; Maltese, G; Lepori, S; Comerci, G; Stefanetti, M; Ditto, A; Martinelli, F; Chiappa, V; Lorusso, D
Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis
2019-01-01 Lorusso, D; Sabatucci, I; Maltese, G; Lepori, S; Tripodi, E; Bogani, G; Raspagliesi, F.
Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance
2020-01-01 Lorusso, D; García-Donas, J; Sehouli, J; Joly, F
Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy"
2017-01-01 Bogani, G; Signorelli, M; Chiappa, V; Carcangiu, Ml; Martinelli, F; Paolini, B; Leone Roberti Maggiore, U; Gennaro, M; Borghi, C; Scaffa, C; Ditto, A; Lorusso, D; Raspagliesi, F.
Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers
2017-01-01 Raspagliesi, F; Bogani, G; Ditto, A; Martinelli, F; Chiappa, V; Borghi, C; Scaffa, C; Morano, F; Maltese, G; Lorusso, D
Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors
2019-01-01 De Giorgi, U; Casadei, C; Bergamini, A; Attademo, L; Cormio, G; Lorusso, D; Pignata, S; Mangili, G.
Investigating the Role of Minimally Invasive Radical Hysterectomy in Cervical Cancer
2020-01-01 Bogani, G; Ditto, A; Martinelli, F; Chiappa, V; Leone Roberti Maggiore, U; Lorusso, D; Raspagliesi, F
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
2020-01-01 Cecere, Sc; Giannone, G; Salutari, V; Arenare, L; Lorusso, D; Ronzino, G; Lauria, R; Cormio, G; Carella, C; Scollo, P; Ghizzoni, V; Raspagliesi, F; Di Napoli, M; Mazzoni, E; Marchetti, C; Bergamini, A; Orditura, M; Valabrega, G; Scambia, G; Maltese, G; De Matteis, E; Cardalesi, C; Loizzi, V; Boccia, S; Naglieri, E; Scandurra, G; Pignata, S.
FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results
2016-01-01 Alessi, A; Martinelli, F; Padovano, B; Serafini, G; Lorusso, D; Lorenzoni, A; Ditto, A; Lecce, F; Mira, M; Donfrancesco, C; Raspagliesi, F; Crippa, F
Chemotherapy-free treatments: Are we ready for prime time?
2019-01-01 Lorusso, D.; Pignata, S.; Gonzalez-Martin, A.
Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
2018-01-01 Lorusso, D; Tripodi, E; Maltese, G; Lepori, S; Sabatucci, I; Bogani, G; Raspagliesi, F
Tailoring adjuvant treatment in patients with uterine cancer
2018-01-01 Bogani, G; Chiappa, V; Lorusso, D; Raspagliesi, F
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
2021-01-01 Coleman, R. L.; Lorusso, D.; Gennigens, C.; Gonzalez-Martin, A.; Randall, L.; Cibula, D.; Lund, B.; Woelber, L.; Pignata, S.; Forget, F.; Redondo, A.; Vindelov, S. D.; Chen, M.; Harris, J. R.; Smith, M.; Nicacio, L. V.; Teng, M. S. L.; Laenen, A.; Rangwala, R.; Manso, L.; Mirza, M.; Monk, B. J.; Vergote, I.; Raspagliesi, F.; Melichar, B.; Gaba Garcia, L.; Jackson, A.; Henry, S.; Kral, Z.; Harter, P.; De Giorgi, U.; Bjurberg, M.; Gold, M.; O'Malley, D.; Honhon, B.; Vulsteke, C.; De Cuypere, E.; Denys, H.; Baurain, J. -F.; Zamagni, C.; Tenney, M.; Gordinier, M.; Bradley, W.; Schlumbrecht, M.; Spirtos, N.; Concin, N.; Mahner, S.; Scambia, G.; Leath, C.; Farias-Eisner, R.; Cohen, J.; Muller, C.; Bhatia, S.
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients
2003-01-01 Lorusso, D; Ferrandina, G; Greggi, S; Gadducci, A; Pignata, S; Tateo, S; Biamonte, R; Manzione, L; Di Vagno, G; Ferrau, F; Scambia, G
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
2019-01-01 Ray-Coquard, I; Pautier, P; Pignata, S; Pérol, D; González-Martín, A; Berger, R; Fujiwara, K; Vergote, I; Colombo, N; Mäenpää, J; Selle, F; Sehouli, J; Lorusso, D; Guerra Alía, Em; Reinthaller, A; Nagao, S; Lefeuvre-Plesse, C; Canzler, U; Scambia, G; Lortholary, A; Marmé, F; Combe, P; de Gregorio, N; Rodrigues, M; Buderath, P; Dubot, C; Burges, A; You, B; Pujade-Lauraine, E; Harter, P; PAOLA-1, Investigators.
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
2019-01-01 González-Martín, A; Pothuri, B; Vergote, I; DePont Christensen, R; Graybill, W; Mirza, Mr; Mccormick, C; Lorusso, D; Hoskins, P; Freyer, G; Baumann, K; Jardon, K; Redondo, A; Moore, Rg; Vulsteke, C; O'Cearbhaill, Re; Lund, B; Backes, F; Barretina-Ginesta, P; Haggerty, Af; Rubio-Pérez, Mj; Shahin, Ms; Mangili, G; Bradley, Wh; Bruchim, I; Sun, K; Malinowska, Ia; Li, Y; Gupta, D; Monk, Bj; PRIMA/ENGOT-OV26/GOG-3012, Investigators.
The impact of morcellation on survival outcomes of undiagnosed uterine sarcoma
2018-01-01 Raspagliesi, F; Bogani, G; Lorusso, D
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma | 1-gen-2020 | Oza, Am; Lorusso, D; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; Weberpals, Ji; Clamp, Ar; Scambia, G; Leary, A; Holloway, Rw; Gancedo Margarita, A; Fong, Pc; Goh, Jc; O'Malley, Dm; Armstrong, Dk; Banerjee, S; García-Donas, J; Swisher, Em; Cella, D; Meunier, J; Goble, S; Cameron, T; Maloney, L; Mörk, A; Bedel, J; Ledermann, Ja; Coleman, Rl | |
| Multicentre Italian Trials in Ovarian cancer (MITO) translational group. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study | 1-gen-2016 | Bagnoli, M; Canevari, S; Califano, D; Losito, S; Maio, Md; Raspagliesi, F; Carcangiu ML, ; Toffoli, G; Cecchin, E; Sorio, R; Canzonieri, V; Russo, D; Scognamiglio, G; Chiappetta, G; Baldassarre, G; Lorusso, D; Scambia, G; Zannoni, Gf; Savarese, A; Carosi M, ; Scollo, P; Breda, E; Murgia, V; Perrone, F; Pignata, S; De Cecco, L; Mezzanzanica, D | |
| WEEKLY BOLUS TOPOTECAN IN ADVANCED OR RECURRENT GYNAECOLOGICAL CANCERS | 1-gen-2009 | Lorusso, D; Mainenti, S.; Pietragalla, A.; De Vincenzo, R. P.; Testa, A.; Di Stefano, M. G.; Masciullo, V; Scambia, G. | |
| Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage IIIC-IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study | 1-gen-2018 | Raspagliesi, F; Bogani, G; Matteucci, L; Casarin, J; Sabatucci, I; Tamberi, S; Arcangeli, V; Maltese, G; Lepori, S; Comerci, G; Stefanetti, M; Ditto, A; Martinelli, F; Chiappa, V; Lorusso, D | |
| Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis | 1-gen-2019 | Lorusso, D; Sabatucci, I; Maltese, G; Lepori, S; Tripodi, E; Bogani, G; Raspagliesi, F. | |
| Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance | 1-gen-2020 | Lorusso, D; García-Donas, J; Sehouli, J; Joly, F | |
| Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy" | 1-gen-2017 | Bogani, G; Signorelli, M; Chiappa, V; Carcangiu, Ml; Martinelli, F; Paolini, B; Leone Roberti Maggiore, U; Gennaro, M; Borghi, C; Scaffa, C; Ditto, A; Lorusso, D; Raspagliesi, F. | |
| Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers | 1-gen-2017 | Raspagliesi, F; Bogani, G; Ditto, A; Martinelli, F; Chiappa, V; Borghi, C; Scaffa, C; Morano, F; Maltese, G; Lorusso, D | |
| Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors | 1-gen-2019 | De Giorgi, U; Casadei, C; Bergamini, A; Attademo, L; Cormio, G; Lorusso, D; Pignata, S; Mangili, G. | |
| Investigating the Role of Minimally Invasive Radical Hysterectomy in Cervical Cancer | 1-gen-2020 | Bogani, G; Ditto, A; Martinelli, F; Chiappa, V; Leone Roberti Maggiore, U; Lorusso, D; Raspagliesi, F | |
| Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome | 1-gen-2020 | Cecere, Sc; Giannone, G; Salutari, V; Arenare, L; Lorusso, D; Ronzino, G; Lauria, R; Cormio, G; Carella, C; Scollo, P; Ghizzoni, V; Raspagliesi, F; Di Napoli, M; Mazzoni, E; Marchetti, C; Bergamini, A; Orditura, M; Valabrega, G; Scambia, G; Maltese, G; De Matteis, E; Cardalesi, C; Loizzi, V; Boccia, S; Naglieri, E; Scandurra, G; Pignata, S. | |
| FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results | 1-gen-2016 | Alessi, A; Martinelli, F; Padovano, B; Serafini, G; Lorusso, D; Lorenzoni, A; Ditto, A; Lecce, F; Mira, M; Donfrancesco, C; Raspagliesi, F; Crippa, F | |
| Chemotherapy-free treatments: Are we ready for prime time? | 1-gen-2019 | Lorusso, D.; Pignata, S.; Gonzalez-Martin, A. | |
| Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy | 1-gen-2018 | Lorusso, D; Tripodi, E; Maltese, G; Lepori, S; Sabatucci, I; Bogani, G; Raspagliesi, F | |
| Tailoring adjuvant treatment in patients with uterine cancer | 1-gen-2018 | Bogani, G; Chiappa, V; Lorusso, D; Raspagliesi, F | |
| Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study | 1-gen-2021 | Coleman, R. L.; Lorusso, D.; Gennigens, C.; Gonzalez-Martin, A.; Randall, L.; Cibula, D.; Lund, B.; Woelber, L.; Pignata, S.; Forget, F.; Redondo, A.; Vindelov, S. D.; Chen, M.; Harris, J. R.; Smith, M.; Nicacio, L. V.; Teng, M. S. L.; Laenen, A.; Rangwala, R.; Manso, L.; Mirza, M.; Monk, B. J.; Vergote, I.; Raspagliesi, F.; Melichar, B.; Gaba Garcia, L.; Jackson, A.; Henry, S.; Kral, Z.; Harter, P.; De Giorgi, U.; Bjurberg, M.; Gold, M.; O'Malley, D.; Honhon, B.; Vulsteke, C.; De Cuypere, E.; Denys, H.; Baurain, J. -F.; Zamagni, C.; Tenney, M.; Gordinier, M.; Bradley, W.; Schlumbrecht, M.; Spirtos, N.; Concin, N.; Mahner, S.; Scambia, G.; Leath, C.; Farias-Eisner, R.; Cohen, J.; Muller, C.; Bhatia, S. | |
| Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients | 1-gen-2003 | Lorusso, D; Ferrandina, G; Greggi, S; Gadducci, A; Pignata, S; Tateo, S; Biamonte, R; Manzione, L; Di Vagno, G; Ferrau, F; Scambia, G | |
| Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | 1-gen-2019 | Ray-Coquard, I; Pautier, P; Pignata, S; Pérol, D; González-Martín, A; Berger, R; Fujiwara, K; Vergote, I; Colombo, N; Mäenpää, J; Selle, F; Sehouli, J; Lorusso, D; Guerra Alía, Em; Reinthaller, A; Nagao, S; Lefeuvre-Plesse, C; Canzler, U; Scambia, G; Lortholary, A; Marmé, F; Combe, P; de Gregorio, N; Rodrigues, M; Buderath, P; Dubot, C; Burges, A; You, B; Pujade-Lauraine, E; Harter, P; PAOLA-1, Investigators. | |
| Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | 1-gen-2019 | González-Martín, A; Pothuri, B; Vergote, I; DePont Christensen, R; Graybill, W; Mirza, Mr; Mccormick, C; Lorusso, D; Hoskins, P; Freyer, G; Baumann, K; Jardon, K; Redondo, A; Moore, Rg; Vulsteke, C; O'Cearbhaill, Re; Lund, B; Backes, F; Barretina-Ginesta, P; Haggerty, Af; Rubio-Pérez, Mj; Shahin, Ms; Mangili, G; Bradley, Wh; Bruchim, I; Sun, K; Malinowska, Ia; Li, Y; Gupta, D; Monk, Bj; PRIMA/ENGOT-OV26/GOG-3012, Investigators. | |
| The impact of morcellation on survival outcomes of undiagnosed uterine sarcoma | 1-gen-2018 | Raspagliesi, F; Bogani, G; Lorusso, D |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista26879
Data di pubblicazione
- In corso di stampa6
- 2020 - 20269083
- 2010 - 201911532
- 2000 - 20094500
- 1990 - 19991429
- 1980 - 1989306
- 1975 - 197923
Editore
- Edition AERCV1
- Elsevier1
- Futura Publishing Company1
- Grafica Luigi Monti s.r.l.1
- Karger, Basel1
- Mosby1
- sn1
- Springer-Verlag1
- Thieme1
Rivista
- DIGESTIVE AND LIVER DISEASE368
- EUROPEAN JOURNAL OF NUCLEAR MEDIC...258
- ANNALS OF ONCOLOGY243
- CANCERS227
- THE JOURNAL OF NUCLEAR MEDICINE220
- PLOS ONE212
- EUROPEAN JOURNAL OF CANCER205
- GASTROINTESTINAL ENDOSCOPY193
- JOURNAL OF CLINICAL MEDICINE182
- ALLERGY180
Keyword
- Humans2101
- Female1005
- Male964
- Middle Aged745
- Aged643
- Adult550
- COVID-19415
- Treatment Outcome359
- Animals321
- Retrospective Studies262
Lingua
- eng19160
- ita408
- spa13
- fre11
- ger8
- enm3
- por2
- chi1
Accesso al fulltext
- no fulltext24626
- reserved1362
- open891